Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines.

ABSTRACT: The prognosis of patients with pancreatic cancer continues to remain dismal, even though numerous trials have been conducted to establish more effective therapies in Japan and throughout the world. Recent advances in treatment have been characterized by the use of novel combinations of conventional cytotoxic chemotherapies. Especially in Japan, S-1 has become one of the most widely used cytotoxic agents for the treatment of pancreatic cancer, after clinical evidence was established of the survival benefit offered by this drug for patients with resectable or unresectable pancreatic cancer. Unfortunately, with the exception of erlotinib, no targeted treatment strategies have been approved for pancreatic cancer. However, following an increase in interest in drug development in recent years, p

SUBMITTER: Okusaka T 

PROVIDER: S-EPMC7080663 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature